DUPA 是谷氨酸脲，在药物偶联中作为靶向部分，可选择靶向性地将细胞毒性药物递送到前列腺癌细胞。

DUPA is used as the targeting moiety to actively deliver DTX for treatment of Prostate-Specific Membrane Antigen (PSMA) expressing prostate cancer.

DUPA is used as the targeting moiety to actively deliver Docetaxel (DTX) for treatment of prostate-specific membrane antigen (PSMA) expressing prostate cancer.

As determined by loss of body weight and death of treated mice,DUPA-indenoisoquinoline conjugate induces a complete cessation of tumor growth with no toxicity[2].

302941-52-2

C11H16N2O9

320.25

N,N''-Carbonylbis[L-glutamic acid];(2S,2'S)-2,2'-Carbonylbis(Azanediyl)Dipentanedioic Acid

H2O:140 mg/mL (437.16 mM)
DMSO:280 mg/mL (874.32 mM)
Powder: -20°C for 3 years
In solvent: -80°C for 2 years